Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37
Abstract Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed.1 However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning.2 Several of these viral variants have the potential to partially escape neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that mimics physiological conditions. We found only small decreases in neutralization against B.1.526 and an intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America3 and was detected in Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.07.21.21260961 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI032245890 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI032245890 | ||
| 003 | DE-627 | ||
| 005 | 20240425104539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210724s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.21.21260961 |2 doi | |
| 035 | |a (DE-627)XBI032245890 | ||
| 035 | |a (biorXiv)10.1101/2021.07.21.21260961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carreño, Juan Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed.1 However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning.2 Several of these viral variants have the potential to partially escape neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that mimics physiological conditions. We found only small decreases in neutralization against B.1.526 and an intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America3 and was detected in Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Alshammary, Hala |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Gagandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Raskin, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Amanat, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Amoako, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Reiche, Ana Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a van de Guchte, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Awawda, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Banu, Radhika |e verfasserin |4 aut | |
| 700 | 1 | |a Beach, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Bermúdez-González, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Bielak, Dominika |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Liyong |e verfasserin |4 aut | |
| 700 | 1 | |a Chernet, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Parnavi |e verfasserin |4 aut | |
| 700 | 1 | |a Fabre, Shelcie |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreri, Emily. D. |e verfasserin |4 aut | |
| 700 | 1 | |a Floda, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Gleason, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabata, Hisaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Zenab |e verfasserin |4 aut | |
| 700 | 1 | |a Kleiner, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Jurczyszak, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Matthews, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Mendez, Wanni |e verfasserin |4 aut | |
| 700 | 1 | |a Mulder, Lubbertus CF |e verfasserin |4 aut | |
| 700 | 1 | |a Paniz-Mondolfi, Kayla Dr. Alberto E |e verfasserin |4 aut | |
| 700 | 1 | |a Salimbangon, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Saksena, Miti |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Sominsky, Levy |e verfasserin |4 aut | |
| 700 | 1 | |a Tcheou, Johnston |e verfasserin |4 aut | |
| 700 | 1 | |a Srivastava, Komal |e verfasserin |4 aut | |
| 700 | 1 | |a Sordillo, Emilia Mia |e verfasserin |0 (orcid)0000-0001-7787-3051 |4 aut | |
| 700 | 1 | |a Sather, D. Noah |e verfasserin |4 aut | |
| 700 | 1 | |a van Bakel, Harm |e verfasserin |0 (orcid)0000-0002-1376-6916 |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Viviana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ebiom.2021.103626 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.21.21260961 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||